Global /Switzerland /Healthcare /Biotechnology /MMTX

MindMaze Therapeutics Holding S.A.

MMTX

• SIX: MMTX • Delayed

0.3415CHF 24%

0.4223 USD

As of 13 July 2026, MindMaze Therapeutics Holding S.A. has a market cap of $52.03M USD, ranking #30296 globally and #227 in Switzerland. It ranks #2733 in the Healthcare sector, and #530 in the Biotechnology industry.

Global Rank

30296

1d: 0

1w: -29

1m: -

Country Rank

227

1d: 0

1w: 0

1m: -

Sector Rank

2733

1d: 0

1w: 0

1m: -

Industry Rank

530

1d: 0

1w: -1

1m: -

Key Stats

Market Cap

$52.03MUSD

41.97M CHF

Company Profile

Country (HQ)

Switzerland

Sector

Healthcare

Industry

Biotechnology

CEO

Zach Henderson open_in_new

Founded

2025

Website

mindmazetherapeutics.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
24%	-12%	-2.8%	-69%	-89%	-82%	-94%	-94%	-94%

News

Markets

Exchange	Ticker	Price	Quotes
SIX Swiss Exchange (SIX / SWX) MIC: XSWX PRIMARY	MMTX ISIN: CH1251125998 Shares Out.: Shares Outstanding: 169.998M¹ Shares Float: 55.468M² TV: TradingView: SIX: MMTX SA: Stock Analysis: SWX: MMTX YF: Yahoo Finance: MMTX.SW GF: Google Finance: SWX: MMTX BA: Barron's: MMTX MS: Morningstar: XSWX: MMTX	0.3415 CHF	TV: TradingView: SIX: MMTX SA: Stock Analysis: SWX: MMTX YF: Yahoo Finance: MMTX.SW GF: Google Finance: SWX: MMTX BA: Barron's: MMTX MS: Morningstar: XSWX: MMTX
London Stock Exchange (LSE / LON) MIC: XLON	0QKQ ISIN: CH1251125998 TV: TradingView: LSE: 0QKQ SA: Stock Analysis: LON: 0QKQ YF: Yahoo Finance: 0QKQ.L GF: Google Finance: LON: 0QKQ BA: Barron's: 0QKQ MS: Morningstar: XLON: 0QKQ	0.1738 CHF	TV: TradingView: LSE: 0QKQ SA: Stock Analysis: LON: 0QKQ YF: Yahoo Finance: 0QKQ.L GF: Google Finance: LON: 0QKQ BA: Barron's: 0QKQ MS: Morningstar: XLON: 0QKQ

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About MindMaze Therapeutics Holding S.A.

MindMaze Therapeutics Holding SA develops and operates the MindMaze platform that integrates neuroscience and digital therapeutics to address some of the most pressing challenges in neurology. The company was founded in 2025 and is based in Lausanne, Switzerland.

Similar Companies

Industry: Biotechnology (Switzerland)

Name	Market Cap (USD) diff.	PE	Country
Lonza Group AG SIX: LONN	$41.8B 33.71B CHF 80K%	37.2	Switzerland
CRISPR Therapeutics AG NASDAQ: CRSP	$4.88B 9K%	-	Switzerland
C CRISPR Therapeutics AG SET: CRSP03	$4.8B 159.94B THB 9K%	-	Switzerland
PolyPeptide Group AG SIX: PPGN	$1.44B 1.17B CHF 3K%	-	Switzerland
Kuros Biosciences AG SIX: KURN	$1.06B 858.72M CHF 2K%	424.5	Switzerland
BioVersys AG SIX: BIOV	$216.79M 174.86M CHF 317%	-	Switzerland

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 351K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 307K%	19.0	United States
argenx SE EBR: ARGX	$47.33B 41.39B EUR 91K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$45.48B 68.19T KRW 87K%	35.5	South Korea
CSL Ltd. ASX: CSL	$41.98B 60.27B AUD 81K%	29.3	Australia
Celltrion, Inc. KRX: 068270	$28.52B 42.76T KRW 55K%	43.8	South Korea

chevron_leftBack